Tolerx wins $15M milestone; Ore gains drug rights from Roche;

> Tolerx has won a $15 million milestone payment from GlaxoSmithKline on its launch of a late-stage trial of an experimental diabetes therapy. Report

> Ore Pharmaceuticals has acquired the exclusive development rights for the clinical-stage compound romazarit from Roche. Ore release

> Valeant Pharmaceuticals and Med are forming joint ventures in Mexico, Canada and Australia to develop and market new therapies. Report

> Alnylam will get $7.5 million in new federal funds to support its work developing new antiviral drugs. Report

> BioSante Pharmaceuticals has reacquired Elestrin (estradiol gel) from Nycomed, which acquired Bradley Pharmaceuticals--BioSante's previous licensee of Elestrin--last February. BioSante release

> Cardinal Health is considering spinning off its clinical and medical products divisions. Release

> Can Merck boost Singulair sales? Report

> How do different antidepressants stack up? Blood-pressure meds? Diabetes drugs? Do we know? Well, Sen. Max Baucus says he aims to find out: He's introduced a bill that would create an institute for comparative-effectiveness research. Report

> When Biogen Idec announced last week that a potentially fatal brain infection had cropped up again in Tysabri patients, markets reacted swiftly--and negatively. Financial analysts have done some number-crunching to quantify those long-term effects. And the news isn't good. Tysabri report

> The debate over costly oncology meds rages on in the U.K. as the National Institute for Health and Clinical Excellence rejected four high-tech drugs for advanced kidney cancer treatment. NICE report

> The FDA has come up with a lineup of three all-new flu strains for this year's vaccine recipe. Report

> Good news for Roche and GlaxoSmithKline: The U.K. is planning to double its stockpile of anti-flu meds to prepare for a possible pandemic. Report

And Finally.... Federal officials believe that Senator Tom Daschle's objections to the anthrax vaccine angered researcher Bruce Ivins, leading to the anthrax attacks. Report

Suggested Articles

Halozyme CEO Helen Torley discusses how the company stayed alive after its lead program, a treatment for pancreatic cancer, failed in phase 3.

The under-active genes that cause heart problems and poor muscle movement in Down syndrome may also impede the growth of solid tumors, a study found.

The new funding will bankroll Dyne's preclinical programs in three muscle-wasting diseases, as well as discovery-stage work.